Analyst Price Target is $9.60
▲ +56.86% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Omega Therapeutics in the last 3 months. The average price target is $9.60, with a high forecast of $12.00 and a low forecast of $4.00. The average price target represents a 56.86% upside from the last price of $6.12.
Current Consensus is
The current consensus among 5 polled investment analysts is to buy stock in Omega Therapeutics.
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. Its OMEGA Epigenomic Programming platform harnesses the power of epigenetics, as well as the mechanism that controls gene expression and aspect of an organism's life. The company's platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a range without altering native nucleic acid sequences. Its modular and programmable mRNA medicines, and Omega Epigenomic Controllers are designed to target specific epigenomic loci within insulated genomic domains from genome-wide DNA-sequences with single or multiple genes to treat and cure diseases through Precision Genomic Control. The company is advancing a pipeline of development candidates covering a range of disease areas, including oncology, regenerative medicine, multigenic diseases, and select monogenic diseases. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.